Appendix:

‘Table 1: Comparison of Patients on Linagliptn vs. Basal-Bolus Insulin Regimen Undergoing
‘Non-Cardiae Surgery with Randomization BG < 11.1 mmol/L

inagliptin Basal-Bolus prvalue
(087) (n=70)

‘Age years S811 S9a1L Os

Female, n 4855) 31153) O77

BML ky/m2 36.2285 337467 0.08

‘Weight, ke 104.0 # 25.1 96.34 23.1 0.03

Race, n (%) 0.82

White 3514) 2840)

Black 37447) 3347)

Other 146) 913)

Duration of Diabetes, T7s71 84478 082

HDA Te, mol/mol S102 153 3802153 O14

Length of stay, days 465) 3.6) 0.96

(redian, 1QR)

‘Admission diabetes 017

therapy, m (%)

‘No medications 30) 229)

‘OAD onl 59 (68) 46.66)

Tnsulin onl 802) 710)

‘OAD + Insulin 103) 1520

[Type of Surgery. n (%)

Orthopedic 33.8) 30043) 033

‘Abdominal 1103) 467) O18

Urologic 616.9) sa 0.40

‘Amputation 334) 618.6) 019

Gynecologic 7180) 7.00) 078

1x. 616.9) sab 0.40

Head & Neck 1d.) Tay 3099)

Other 157) 913) O51

All data are expressed as mean © SD unless otherwise specified. IQR: interquartile range, OAD:
‘ral antidiabetic agent, L&D: Incision and drainage